$NKTR Headlines AstraZeneca's NDA for Naloxegol
Post# of 102864
Posted On: 02/06/2014 11:03:06 AM
$NKTR Headlines
AstraZeneca's NDA for Naloxegol accepted 3:35 a.m. Nov. 19, 2013 - MarketWatch.com
Nektar Therapeutics shares soar on earnings, new drug prospects 12:31 p.m. Nov. 8, 2013 - Russ Britt
Rough market day for Nektar, while Pharmacyclics and Regeneron soar 5:21 p.m. Sept. 26, 2013 - Russ Britt
Nike shares swoosh higher after earnings 4:53 p.m. Sept. 26, 2013 - Wallace Witkowski
Nektar shares drop 25% after study misses endpoint 3:45 p.m. Sept. 26, 2013 - Wallace Witkowski
FDA grants fast-track status for Nektar drug 10:43 a.m. Nov. 7, 2012 - MarketWatch.com
S&P 500 clears trendline resistance 10:01 a.m. July 30, 2012 - Michael Ashbaugh
Charting the latest tape bomb 10:02 a.m. July 23, 2012 - Michael Ashbaugh
Wednesday’s biggest gaining & declining stocks 5:04 p.m. Feb. 29, 2012 - Kate Gibson
Nektar sells royalties for two drugs 11:31 a.m. Feb. 29, 2012 - MarketWatch.com
S&P 500 vacillates at the March peak 9:47 a.m. April 4, 2011 - Michael Ashbaugh
Wednesday’s biggest gaining and declining stocks 4:24 p.m. Jan. 19, 2011 - Kate Gibson
Monday’s biggest gaining and declining stocks 4:24 p.m. Dec. 13, 2010 - Kate Gibson
Drug indexes hug the flat line 10:57 a.m. Dec. 13, 2010 - Val Brickates Kennedy
Wednesday's biggest gaining and declining stocks 4:40 p.m. March 3, 2010 - MarketWatch
Nasdaq hesitates at the 50-day moving average 9:46 a.m. Feb. 18, 2010 - Michael Ashbaugh
S&P 500 settling into the 2004 trading range? 11:38 a.m. Feb. 1, 2010 - Michael Ashbaugh
S&P pulls in from the 1,100 mark 9:15 a.m. Oct. 16, 2009 - Michael Ashbaugh
U.S. benchmarks survive initial test of the 50-day 9:19 a.m. Oct. 5, 2009 - Michael Ashbaugh
Miners, banks weigh on U.K. market 11:07 a.m. Sept. 21, 2009 - Simon Kennedy
Russell 2000 Rebalance May Bring Huge Buying in Key Stocks 8:29 a.m. Jan. 31, 2014 - 247WallSt.com
Nektar Therapeutics (NKTR) Looks Good: Stock Up 6.8% in Session - Tale of the Tape 8:44 a.m. Jan. 24, 2014 - Zacks.com
Nektar Therapeutics (NKTR) Is Today's Pre-Market Mover With Heavy Volume Stock 8:27 a.m. Jan. 23, 2014 - TheStreet.com
SA PRO: Top Long And Short Ideas, Wednesday January 22 7:30 a.m. Jan. 23, 2014 - Seeking Alpha
Nektar Therapeutics Prices 8.5M Share Offering at $12.75/Share 9:50 p.m. Jan. 22, 2014 - benzinga.com
Cowen names its top biotech stocks with biggest upside to buy in 2014 6:45 p.m. Jan. 22, 2014 - Seeking Alpha
Interesting NKTR Put And Call Options For March 22nd 11:56 a.m. Jan. 22, 2014 - TheStreet.com
Nektar Momentum Continues To Grow 11:52 a.m. Jan. 22, 2014 - Seeking Alpha
Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside 8:54 a.m. Jan. 22, 2014 - 247WallSt.com
Nektar Therapeutics Announces Public Offering of 8.5M Shares of Common Stock 3:14 p.m. Jan. 21, 2014 - benzinga.com
Nektar Therapeutics Is The Seattle Genetics Of San Francisco But It Could Be More 1:29 p.m. Jan. 21, 2014 - Seeking Alpha
Nektar Presents Positive Data from Phase 1 Study of Etirinotecan Pegol in Combination with 5-Flourouracil/Leucovorin at 2014 Gastrointestinal Cancers Symposium 11:34 a.m. Jan. 18, 2014 - benzinga.com
Pipeline Progress at Nektar - Analyst Blog 5:20 p.m. Jan. 16, 2014 - Zacks.com
Piper Jaffray Has Four Biotech Stocks to Buy With Huge Potential 7:20 a.m. Jan. 16, 2014 - 247WallSt.com
Nektar Therapeutics' CEO Presents at 32nd Annual JPMorgan Healthcare Conference (Transcript) 4:05 p.m. Jan. 14, 2014 - Seeking Alpha
Cadence Pharmaceuticals Inc. (CADX) Soars: Stock Adds 13.0% in Session - Tale of the Tape 9:21 a.m. Jan. 14, 2014 - Zacks.com
Time to Buy Nektar Therapeutics (NKTR) After Recent Moving Average Crossover? - Tale of the Tape 7:21 a.m. Jan. 14, 2014 - Zacks.com
Etirinotecan Pegol Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer 7:18 a.m. Jan. 14, 2014 - benzinga.com
Flamel Technologies (FLML) in Focus: Stock Jumps 8.6% - Tale of the Tape 8:37 a.m. Jan. 13, 2014 - Zacks.com
Scorching Hot Biotech Tape: Small-Cap and Mid-Cap Stocks on Fire 8:33 a.m. Jan. 10, 2014 - 247WallSt.com
Nektar Therapeutics Prices Public Offering of Common Stock 9:59 p.m. Jan. 22, 2014 - PR Newswire - PRF
Nektar Therapeutics Announces Public Offering of 8,500,000 Shares of Common Stock 4:10 p.m. Jan. 21, 2014 - PR Newswire - PRF
Nektar Presents Positive Clinical Data from a Phase 1 Study of Etirinotecan Pegol (NKTR-102) in Combination with 5-Flourouracil/Leucovorin at the 2014 Gastrointestinal Cancers Symposium 12:00 p.m. Jan. 18, 2014 - PR Newswire - PRF
Market Technicals Simplified: Inovio Pharma, Sequenom, Nektar Therapeutics, and Discovery Laboratories 7:33 a.m. Jan. 16, 2014 - PR Newswire - PRF
Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer 8:15 a.m. Jan. 14, 2014 - PR Newswire - PRF
First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain 8:00 a.m. Jan. 14, 2014 - PR Newswire - PRF
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA 5:38 p.m. Jan. 8, 2014 - PR Newswire
Addition to Indices, and Stock Price Movements - Research Report on ACADIA Pharmaceuticals, InterMune, Tandem Diabetes Care, Nektar Therapeutics and Greatbatch 8:00 a.m. Dec. 25, 2013 - PR Newswire
AAAResearchReports.com Pre-Market Technical Analysis: Inovio Pharma, Sequenom, Nektar Therapeutics, and Discovery Laboratories 8:23 a.m. Dec. 17, 2013 - PR Newswire
New Research Arrangements, Investor Conference Schedules, Reimbursement Agreements, and NDA Acceptances - Research Report on Quintiles, Insys, HeartWare, Given Imaging, and Nektar 8:00 a.m. Nov. 28, 2013 - PR Newswire
Financing, Special Reports, and Clinical Trial Updates - Research Report on PDL, DexCom, Quintiles, KYTHERA, and Nektar 8:00 a.m. Nov. 20, 2013 - PR Newswire
Morning Research: Inovio Pharma Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc. 9:03 a.m. Nov. 19, 2013 - PR Newswire
New Drug Application For Naloxegol Accepted By United States Food And Drug Administration 7:00 a.m. Nov. 19, 2013 - PR Newswire
Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 9:34 a.m. Nov. 13, 2013 - PR Newswire
Baxter Completes Enrollment in Phase III Clinical Trial of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A 9:00 a.m. Nov. 13, 2013 - BusinessWire
Updates on Clinical Studies and Milestone Revenues - Research Report on Cyberonics, West, Nektar, OraSure, and Akorn 8:00 a.m. Nov. 12, 2013 - PR Newswire
Critical Alerts For Salix Pharmaceuticals, Endo Pharmaceuticals, Nektar Therapeutics, Riverbed Technology, and Ubiquiti Networks Released By InvestorsObserver 9:31 a.m. Nov. 11, 2013 - PR Newswire
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013 4:15 p.m. Nov. 7, 2013 - PR Newswire
Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets 4:00 p.m. Oct. 30, 2013 - PR Newswire
Today's Research: Inovio Pharmaceuticals Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc. 8:00 a.m. Oct. 28, 2013 - PR Newswire
AstraZeneca's NDA for Naloxegol accepted 3:35 a.m. Nov. 19, 2013 - MarketWatch.com
Nektar Therapeutics shares soar on earnings, new drug prospects 12:31 p.m. Nov. 8, 2013 - Russ Britt
Rough market day for Nektar, while Pharmacyclics and Regeneron soar 5:21 p.m. Sept. 26, 2013 - Russ Britt
Nike shares swoosh higher after earnings 4:53 p.m. Sept. 26, 2013 - Wallace Witkowski
Nektar shares drop 25% after study misses endpoint 3:45 p.m. Sept. 26, 2013 - Wallace Witkowski
FDA grants fast-track status for Nektar drug 10:43 a.m. Nov. 7, 2012 - MarketWatch.com
S&P 500 clears trendline resistance 10:01 a.m. July 30, 2012 - Michael Ashbaugh
Charting the latest tape bomb 10:02 a.m. July 23, 2012 - Michael Ashbaugh
Wednesday’s biggest gaining & declining stocks 5:04 p.m. Feb. 29, 2012 - Kate Gibson
Nektar sells royalties for two drugs 11:31 a.m. Feb. 29, 2012 - MarketWatch.com
S&P 500 vacillates at the March peak 9:47 a.m. April 4, 2011 - Michael Ashbaugh
Wednesday’s biggest gaining and declining stocks 4:24 p.m. Jan. 19, 2011 - Kate Gibson
Monday’s biggest gaining and declining stocks 4:24 p.m. Dec. 13, 2010 - Kate Gibson
Drug indexes hug the flat line 10:57 a.m. Dec. 13, 2010 - Val Brickates Kennedy
Wednesday's biggest gaining and declining stocks 4:40 p.m. March 3, 2010 - MarketWatch
Nasdaq hesitates at the 50-day moving average 9:46 a.m. Feb. 18, 2010 - Michael Ashbaugh
S&P 500 settling into the 2004 trading range? 11:38 a.m. Feb. 1, 2010 - Michael Ashbaugh
S&P pulls in from the 1,100 mark 9:15 a.m. Oct. 16, 2009 - Michael Ashbaugh
U.S. benchmarks survive initial test of the 50-day 9:19 a.m. Oct. 5, 2009 - Michael Ashbaugh
Miners, banks weigh on U.K. market 11:07 a.m. Sept. 21, 2009 - Simon Kennedy
Russell 2000 Rebalance May Bring Huge Buying in Key Stocks 8:29 a.m. Jan. 31, 2014 - 247WallSt.com
Nektar Therapeutics (NKTR) Looks Good: Stock Up 6.8% in Session - Tale of the Tape 8:44 a.m. Jan. 24, 2014 - Zacks.com
Nektar Therapeutics (NKTR) Is Today's Pre-Market Mover With Heavy Volume Stock 8:27 a.m. Jan. 23, 2014 - TheStreet.com
SA PRO: Top Long And Short Ideas, Wednesday January 22 7:30 a.m. Jan. 23, 2014 - Seeking Alpha
Nektar Therapeutics Prices 8.5M Share Offering at $12.75/Share 9:50 p.m. Jan. 22, 2014 - benzinga.com
Cowen names its top biotech stocks with biggest upside to buy in 2014 6:45 p.m. Jan. 22, 2014 - Seeking Alpha
Interesting NKTR Put And Call Options For March 22nd 11:56 a.m. Jan. 22, 2014 - TheStreet.com
Nektar Momentum Continues To Grow 11:52 a.m. Jan. 22, 2014 - Seeking Alpha
Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside 8:54 a.m. Jan. 22, 2014 - 247WallSt.com
Nektar Therapeutics Announces Public Offering of 8.5M Shares of Common Stock 3:14 p.m. Jan. 21, 2014 - benzinga.com
Nektar Therapeutics Is The Seattle Genetics Of San Francisco But It Could Be More 1:29 p.m. Jan. 21, 2014 - Seeking Alpha
Nektar Presents Positive Data from Phase 1 Study of Etirinotecan Pegol in Combination with 5-Flourouracil/Leucovorin at 2014 Gastrointestinal Cancers Symposium 11:34 a.m. Jan. 18, 2014 - benzinga.com
Pipeline Progress at Nektar - Analyst Blog 5:20 p.m. Jan. 16, 2014 - Zacks.com
Piper Jaffray Has Four Biotech Stocks to Buy With Huge Potential 7:20 a.m. Jan. 16, 2014 - 247WallSt.com
Nektar Therapeutics' CEO Presents at 32nd Annual JPMorgan Healthcare Conference (Transcript) 4:05 p.m. Jan. 14, 2014 - Seeking Alpha
Cadence Pharmaceuticals Inc. (CADX) Soars: Stock Adds 13.0% in Session - Tale of the Tape 9:21 a.m. Jan. 14, 2014 - Zacks.com
Time to Buy Nektar Therapeutics (NKTR) After Recent Moving Average Crossover? - Tale of the Tape 7:21 a.m. Jan. 14, 2014 - Zacks.com
Etirinotecan Pegol Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer 7:18 a.m. Jan. 14, 2014 - benzinga.com
Flamel Technologies (FLML) in Focus: Stock Jumps 8.6% - Tale of the Tape 8:37 a.m. Jan. 13, 2014 - Zacks.com
Scorching Hot Biotech Tape: Small-Cap and Mid-Cap Stocks on Fire 8:33 a.m. Jan. 10, 2014 - 247WallSt.com
Nektar Therapeutics Prices Public Offering of Common Stock 9:59 p.m. Jan. 22, 2014 - PR Newswire - PRF
Nektar Therapeutics Announces Public Offering of 8,500,000 Shares of Common Stock 4:10 p.m. Jan. 21, 2014 - PR Newswire - PRF
Nektar Presents Positive Clinical Data from a Phase 1 Study of Etirinotecan Pegol (NKTR-102) in Combination with 5-Flourouracil/Leucovorin at the 2014 Gastrointestinal Cancers Symposium 12:00 p.m. Jan. 18, 2014 - PR Newswire - PRF
Market Technicals Simplified: Inovio Pharma, Sequenom, Nektar Therapeutics, and Discovery Laboratories 7:33 a.m. Jan. 16, 2014 - PR Newswire - PRF
Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer 8:15 a.m. Jan. 14, 2014 - PR Newswire - PRF
First Subjects Dosed in Phase 1 Clinical Study of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker to Treat Neuropathic Pain 8:00 a.m. Jan. 14, 2014 - PR Newswire - PRF
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA 5:38 p.m. Jan. 8, 2014 - PR Newswire
Addition to Indices, and Stock Price Movements - Research Report on ACADIA Pharmaceuticals, InterMune, Tandem Diabetes Care, Nektar Therapeutics and Greatbatch 8:00 a.m. Dec. 25, 2013 - PR Newswire
AAAResearchReports.com Pre-Market Technical Analysis: Inovio Pharma, Sequenom, Nektar Therapeutics, and Discovery Laboratories 8:23 a.m. Dec. 17, 2013 - PR Newswire
New Research Arrangements, Investor Conference Schedules, Reimbursement Agreements, and NDA Acceptances - Research Report on Quintiles, Insys, HeartWare, Given Imaging, and Nektar 8:00 a.m. Nov. 28, 2013 - PR Newswire
Financing, Special Reports, and Clinical Trial Updates - Research Report on PDL, DexCom, Quintiles, KYTHERA, and Nektar 8:00 a.m. Nov. 20, 2013 - PR Newswire
Morning Research: Inovio Pharma Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc. 9:03 a.m. Nov. 19, 2013 - PR Newswire
New Drug Application For Naloxegol Accepted By United States Food And Drug Administration 7:00 a.m. Nov. 19, 2013 - PR Newswire
Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 9:34 a.m. Nov. 13, 2013 - PR Newswire
Baxter Completes Enrollment in Phase III Clinical Trial of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A 9:00 a.m. Nov. 13, 2013 - BusinessWire
Updates on Clinical Studies and Milestone Revenues - Research Report on Cyberonics, West, Nektar, OraSure, and Akorn 8:00 a.m. Nov. 12, 2013 - PR Newswire
Critical Alerts For Salix Pharmaceuticals, Endo Pharmaceuticals, Nektar Therapeutics, Riverbed Technology, and Ubiquiti Networks Released By InvestorsObserver 9:31 a.m. Nov. 11, 2013 - PR Newswire
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013 4:15 p.m. Nov. 7, 2013 - PR Newswire
Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets 4:00 p.m. Oct. 30, 2013 - PR Newswire
Today's Research: Inovio Pharmaceuticals Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc. 8:00 a.m. Oct. 28, 2013 - PR Newswire
(0)
(0)